Compare WAVE & SCNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | WAVE | SCNX |
|---|---|---|
| Founded | 2011 | 2010 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | Electric Utilities: Central | Other Pharmaceuticals |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 47.5M | 16.2M |
| IPO Year | 2021 | 2019 |
| Metric | WAVE | SCNX |
|---|---|---|
| Price | $5.96 | $0.37 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $1.50 |
| AVG Volume (30 Days) | 9.6K | ★ 699.7K |
| Earning Date | 05-07-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $3,831,778.00 |
| Revenue This Year | $436.84 | $1,097.38 |
| Revenue Next Year | N/A | $239.80 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 30.72 |
| 52 Week Low | $4.52 | $0.24 |
| 52 Week High | $10.87 | $2.60 |
| Indicator | WAVE | SCNX |
|---|---|---|
| Relative Strength Index (RSI) | 37.21 | 41.26 |
| Support Level | $5.53 | $0.37 |
| Resistance Level | $6.49 | $0.43 |
| Average True Range (ATR) | 0.44 | 0.03 |
| MACD | -0.03 | -0.01 |
| Stochastic Oscillator | 28.30 | 13.66 |
Eco Wave Power Global AB is a Sweden-based wave energy company engaged in the development of a smart and cost-efficient wave energy conversion, or WEC, technology that converts ocean and sea waves into clean electricity. Its WEC technology employs units of point absorber floating devices, referred to as floaters, which are installed on existing marine structures such as piers, breakwaters, and jetties, or in locations in which such marine structures are required. Geographically, it has a presence in Israel, the USA, and Mexico.
Scienture Holdings Inc is a comprehensive health services and pharmaceutical product company. The group focused on the commercialization and development of products for the treatment of cardiovascular (CVS) and Central Nervous System (CNS) diseases. Scienture LLC launched its first commercial product for hypertension and is in the process of commercializing its second product for the treatment of opioid overdose. Its development pipeline consists of a broad range of novel product candidates including new potential treatments for migraine, thrombosis, pain and other related disorders.